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Abstract: Translational research aims to provide direct support for advancing novel treatment 
approaches in oncology towards improving patient outcomes. Preclinical studies have a central role 
in this process and the ability to accurately model biological and physical aspects of the clinical 
scenario in radiation oncology is critical to translational success. The use of small animal irradiators 
with disease relevant mouse models and advanced in vivo imaging approaches offers unique 
possibilities to interrogate the radiotherapy response of tumors and normal tissues with high 
potential to translate to improvements in clinical outcomes. The present review highlights the 
current technology and applications of small animal irradiators, and explores how these can be 
combined with molecular and functional imaging in advanced preclinical radiotherapy research. 
Keywords: preclinical radiotherapy; functional imaging; small animal irradiators; radiobiology; 
radiation oncology 
 
1. Introduction 
Since the introduction of the linear accelerator into the practice of radiation oncology during the 
1950s, the discipline has undergone major technology changes that have significantly advanced all 
stages of the radiotherapy process from treatment planning to delivery and verification. These 
innovations have resulted in an unparalleled ability to delineate target volumes, conform radiation 
dose and irradiate under image guidance [1], which have translated to better tumor control and 
reduced toxicity in many cancer types. Despite these advances, it is unlikely that radiotherapy 
technology has reached its zenith, with many developments in molecular and functional imaging, 
treatment adaptation and particle therapy yet to be fully realized in the clinic [2].  
In contrast, the impact of biologically driven strategies in radiation oncology has been less 
substantial. This is evidenced by the implementation of most advanced radiotherapy techniques on 
the basis of technology rather than a comprehensive understanding of radiobiological response, 
highlighting the need for advanced preclinical systems capable of modelling aspects of human 
disease under clinically relevant radiation exposure conditions. In addition, several radiotherapy 
clinical trials have reported null outcomes, an issue that was examined by the National Cancer 
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Institute (NCI) Radiation Research Program (RRP) at a workshop aiming to better understand these 
findings and to try to improve the success of future trials [3]. 
From radiotherapy trials reporting negative and null outcomes, an intriguing example is that of 
the phase 3 Radiotherapy Oncology Trial Group (RTOG) 0617 study. This aimed to compare 
standard-dose versus dose escalation with concurrent chemotherapy and the addition of cetuximab 
in patients with inoperable stage III non-small-cell lung cancer (NSCLC). The study failed to 
demonstrate overall survival benefit at the higher dose of 74 Gy, compared with the lower, standard 
dose of 60 Gy [4], and further reported 17 deaths in the high dose arms compared to 7 in the lower 
dose cohort. The causes of these unexpected findings have been explored with secondary analysis 
suggesting that deaths related to the effects of dose to the heart and lung are the most likely 
explanation of the findings, and these continue to be discussed [5]. 
Importantly, trials such as a RTOG 0617 need to be reverse translated using relevant preclinical 
models to gain de novo mechanistic insight into the clinical benefits and risks of dose escalation. Part 
of the recommendations proposed by the NCI RRP group have included the requirement for robust 
preclinical supporting data to guide subsequent clinical trials. In addition, Stone et al., surveyed data 
from 125 published reports which tested the interaction of 10 drug-radiation combinations and 
provided comprehensive recommendations for improved preclinical testing [6]. This has also been 
supported by further recommendations from Coleman et al., aiming at improve the predictive power 
of preclinical models in developing radiotherapy clinical trials [7]. Cumulatively, these reports clearly 
highlight the need for robust preclinical supporting data in translationally relevant disease models 
to justify radiotherapy clinical trials. In this context, it is essential that preclinical models in 
radiobiology research accurately reflect modern clinical practice, in terms of both biological model 
and physical radiation exposure conditions [8]. These approaches should also be further synergized 
with anatomical, functional and molecular imaging to optimize radiotherapy planning and response 
monitoring and maximize potential for translation. In this article, we review the technology of small 
animal irradiators and preclinical imaging techniques to identify key opportunities for translational 
research that may impact the future success rate of radiotherapy clinical trials. 
2. Small Animal Radiotherapy: Rationale and Technology 
Since the first report of the tissue sparing effects from fractionation in ram testes more than 100 
years ago [9], small animal models have been widely applied in radiobiological studies predicated 
on the basis of genetic and physiological similarities with humans [10]. In particular, mouse models 
have contributed significantly to the advancement of biomedical research [11]. Recent genome 
editing technologies continue to allow a wide spectrum of gain- and loss-of-function mutations to be 
investigated along with evaluation of novel therapies in defined genomic backgrounds. In addition, 
the implantation of human tissue into NOD-scid-γ (NSG) mice with partially reconstituted immune 
systems can help to recapitulate aspects of the patient immune response during treatment through 
humanized mouse models [12]. Whilst no ideal mouse model exists to truly recapitulate the human 
setting, it is important that contemporary disease models are used with advanced irradiation 
techniques to closely mimic clinical scenarios and maximize the potential to deliver translationally 
relevant datasets [13]. 
Classic radiobiology experiments have been performed using broad fields from fixed sources 
and shielding to target the beam. Some of these experiments involved the irradiation of large volumes 
(usually whole body or whole thorax) which did not require precision image guidance, however, 
these procedures have high levels of uncertainty due to inaccurate beam targeting, as highlighted in 
Figure 1. 
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Figure 1. Schematic diagram demonstrating the evolution of conventional radiobiology to image-
guided preclinical radiotherapy and molecular imaging. These changes are a major refinement of 
conventional techniques and have resulted in improved precision and accuracy. Overall, these 
advanced approaches have reduced study sizes in radiobiology studies required to obtain statistical 
power by reducing dose uncertainty, error and allowing longitudinal analysis. 
Similar to clinical techniques, modern radiobiology studies aim to irradiate small target volumes 
with high levels of precision and accuracy. Devices capable of performing image-guided irradiation 
in small animals have been developed over the last 10 years by a number of investigators and vendors 
(Table 1). Two systems have been made commercially available: The Small Animal Radiotherapy 
Research Platform (SARRP) from Xstrahl Life Sciences developed at Johns Hopkins University [13] 
and the X-Rad SmART from Precision X-ray Inc., developed at Princess Margaret Hospital [14]. In 
addition, several other systems have been designed and implemented at a number of institutions 
across the world using approaches consisting of rotating or fixed gantries with cone beam computed 
tomography (CBCT) detectors or conversions of micro-CT devices. Details of these systems and their 
characteristics are summarized in Table 1. 
Table 1. Summary of small animal radiotherapy systems and individual characteristics. 
Research 
Platform 
Vendor 
Research 
Institute 
Beam 
Energy 
(KeV) 
Dose 
Rate 
(Gy/ 
Min) 
Beam 
Collimation 
Accuracy 
(mm) 
Image 
Guidance 
Treatment 
Planning 
System 
Reference 
Commercially available 
SARRP 1 
Xstrahl Life 
Sciences 
5–225 1–4 
Aperture 
MVC 
0.2 
CBCT 
BLT 
Muriplan [14,15] 
X-RAD 225Cx 
SmART 2 
Precision X-
ray 
5–225 0.01–4 Aperture 0.2 
CBCT 
BLI 
SmART-
Plan  
[16] 
Non-commercial 
iSMAART 
University of 
Miami, USA 
45–225 2.5–4 Aperture 0.4 
CBCT 
BLT 
FLT 
In house [17–19] 
SAIGRT 3 
Technical 
University of 
Dresden, 
Germany 
10–225 1–4 
Aperture 
MVC 
 
0.1 CBCT In house [20] 
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SACRTD 4 
University of 
Arkansas, 
AR, USA 
60–225 0.4–3 Aperture 0.2 CBCT In house [21] 
Micro-CT 
based 
radiotherapy 
devices 
Stanford 
University, 
USA 
70–120 2 Aperture <0.1 CBCT In house [22] 
Heidelberg 
University, 
Germany 
10–160 4.5–6.4 Aperture <1 CBCT In house [23] 
The 
University of 
Western 
Ontario, 
Canada 
70–140 2 
Jaw 
Collimation 
0.1 CBCT In house [24] 
1 Small animal radiotherapy research platform (SARRP); 2 Small animal radiotherapy (SmART); 3 Small animal 
image guided radiotherapy (SAIGRT); 4 Small animal conformal radiotherapy device (SACRTD). 
To complement these platforms, dedicated treatment planning systems (TPS) analogous to those 
used clinically are required for accurate dose calculations. These have been developed using the 
superposition convolution algorithm [25], Monte Carlo simulations [15] or in-house dose engines [26]. 
Preclinical TPS aim to efficiently solve the challenges associated with tissue segmentation and dose 
calculation relating to photon scattering for very small fields and differences in the energy absorption 
of soft tissues for kilovoltage beams [27]. Although still at a relatively early stage, small animal 
irradiators are rapidly becoming the experimental standard in radiobiology. Previously unachievable 
experimental approaches are now being explored, including the irradiation of small target volumes 
(under 100 mm3) at depth under image guidance from computed tomography (CT), magnetic 
resonance imaging (MRI) and bioluminescence imaging (BLI). 
The integration of small animal irradiators into radiobiology research either, simultaneously or 
sequentially combined with imaging methods such as CT, BLI, positron-emission tomography (PET) 
and MRI, have significantly improved the level of precision and accuracy with which target volumes 
can be irradiated. These strategies have directly impacted animal welfare within the framework of 
the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research 
(NC3Rs). In particular, these improvements are a major refinement from conventional approaches as 
both precision and accuracy has been improved along with the ability to acquire longitudinal 
information from the same animals. Consequently, this has reduced the requirement for large study 
sizes which shown schematically in Figure 1 [28,29]. 
3. Preclinical Imaging: Principles and Technology 
Imaging has focused on the visualization of anatomical regions of interest in the diagnosis and 
staging of disease, as well as monitoring response to therapy. Conventional anatomical imaging 
methods, such as X-ray, fluoroscopy and computed tomography (CT) continue to play a critical role 
in the delineation of macroscopic patient anatomy. However, advances in molecular biology have 
enabled imaging techniques to move beyond structural characterization of malignancy into the realm 
of molecular imaging [30]. This involves the visualization, characterization, and measurement of 
biological processes at the molecular and cellular levels, typically including two- or three-
dimensional imaging using techniques such as PET, Single Photon Emission Computed Tomography 
(SPECT) and BLI [31]. Some of these techniques overlap as functional imaging modalities that are 
used to delineate and measure physiologic functions in organ systems, including techniques such as 
PET, functional MRI and ultrasound. 
Many preclinical imaging techniques were originally developed as clinical imaging procedures 
but have since been reverse translated in the same way modern radiotherapy has been brought to the 
preclinical laboratory. A variety of imaging methods are now available to plan and monitor 
radiotherapy response in a manner analogous to that in the clinic as shown in Figure 2. 
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Figure 2. Schema of different preclinical imaging techniques showing increasing molecular specificity 
and spatial resolution for in vitro and in vivo studies. BLI, bioluminescence imaging; PET, positron-
emission tomography; CT, computed tomography; MRI, magnetic resonance imaging. 
X-ray computed tomography (CT) remains the primary imaging modality in preclinical and 
clinical radiotherapy treatment planning. In small animal CT scanners, X-rays are emitted as a beam 
from the tube, pass through the subject and are detected by a large-area solid-state radiation detector [28]. 
Whilst CT can provide material composition information useful for dose calculation, it has limited 
soft tissue contrast that can complicate identification of targets for treatment as well as volumes of 
radiosensitive tissues to be avoided. 
A variety of molecular imaging technologies have been developed that generate image contrast 
based on functional aspects of tissue including perfusion, gene expression, oxygenation and 
metabolism, rather than anatomical structure [28,32–34]. The most prominent modality used for this 
purpose clinically is positron-emission tomography (PET), a nuclear medicine technique that detects 
and localizes radiation produced by positron-emitting radiopharmaceuticals administered 
exogenously to a subject [35]. Imaging glucose metabolism with 18F-fluorodeoxyglucose (18F-FDG) is 
most commonly used to provide functional information based on increased uptake and glycolysis of 
cancer cells [32,36]. 18F-FDG PET is widely used in cancer diagnosis and screening, yet it is unsuitable 
for tumors in organs with high 18F-FDG non-specific uptake such as the liver. Furthermore, it has 
limited ability to differentiate benign from metastatic lesions and early versus late stage disease [37]. 
The development of many other tracer types has given PET wide applications, particularly in 
the study of tumor metabolism [38]. Some preclinical PET tracers are probes consisting of a targeted 
molecule specific to a biological functional measurement attached to a radioisotope with a favorable 
half-life such as 11C, 15O and 18F. Probes can also be used to image specific molecules based on binding 
of radiolabeled ligands (e.g., α5β3 integrin imaging of tumor vasculature with radiolabeled 
glycosylated RGD (arginine-glycine-aspartate) containing peptides). A list of PET tracers used in 
preclinical studies and their biological targets is summarized in table 2. PET has progressed to offer 
~5 mm spatial resolution and picomolar sensitivity in clinical scanners [39]. Preclinical studies have 
exploited microPET technology with comparable sensitivity and ~1 mm spatial resolution for 
treatment planning and response assessment [28,40]. 
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Table 2. Summary of tracers used in preclinical studies and their biological targets. 
Tracer Targeting Moiety Biological Target Reference 
64Cu Anti-PD-1 
Tumor infiltrating 
lymphocytes 
[41] 
124I Anti-CD4 CD8+ cells [42–44] 
89Zr Anti-CD4 
T-cell reconstitution post-
transplant 
[43] 
89Zr Anti-CD3  
tumor-infiltrating 
lymphocytes 
[44] 
64Cu 
Anti-OX40 T cells activation 
[45] 
Anti-CTLA-4 CTLA-4 visualization 
68Ga/18F PSMA PSMA [46] 
18F-FDG Fluorodeoxyglucose Glucose metabolism [47] 
68Ga-NODAGA-
c(RGDfK) 
RGD (arginine, glycine, aspartate) peptides 
αvβ3 integrins in the tumor 
vasculature 
[48] 
18F-EF5 
2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoro 
propyl)-acetamide 
Hypoxia 
[49,50] 
18F-FAZA 
1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-
nitroimidazole 
18F-FMISO Fluoromisonidazole 
[51–54] 
18F-HX4 
fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-
1,2,3-triazol-1-yl)propan-1-ol 
(18F)F-AraG 
2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoro 
propyl)-acetamide 
fluoro-9-β-D-arabinofuranosyl guanin 
T cell activation [55,56] 
Magnetic resonance imaging (MRI) has become an established medical imaging modality due to 
its superior soft tissue contrast and lack of ionizing radiation dose. MRI is based on combining high-
strength magnetic fields with radiofrequency (RF) detection to exploit atomic nuclei with odd 
numbers of nucleons and thus net magnetic moments [28]. At the microscopic level, net magnetic 
fields in tissue depend on the microenvironment as well as the applied magnetic field, yielding soft 
tissue contrast uniquely characteristic of MRI. Preclinical MRI systems are being implemented for a 
range of applications, including MRI-guided radiation therapy for intracranial, pancreatic and flank 
tumors, immobilization devices, fiducial marker placement and MRI-only based treatment planning 
[57–59]. These methods are well established for mice and rats with technical developments towards 
implementing adaptable registration into existing workflows for small animal radiotherapy [57–59]. 
Other molecular imaging modalities such as BLI have been developed specifically for preclinical 
applications. BLI involves the engineering of cells to express a luciferase enzyme, which catalyzes the 
metabolism of a substrate (luciferin) that generates as a by-product a photon in the visible to near-
infrared wavelength range [49]. Such enzymatic reactions are found natively in organisms including 
bacteria, fireflies, and jellyfish, however, molecular biology methods have allowed integration of 
luciferase into cells in vitro or into animals through the germline. Two-dimensional BLI is now used 
extensively in preclinical cancer biology research to detect, quantify, and localize specific cell types 
[60–62] and is being integrated with preclinical image-guided irradiators for target localization and 
response monitoring. 
The X-Rad SmART (Precision X-ray, Inc, North Branford, CT, USA) offers a configuration in 
which a cooled CCD camera is mounted on the gantry perpendicular to the X-ray beam axis to allow 
two-dimensional BLI data to be collected from the subject and co-registered with the planning CT [15]. 
In contrast, the SARRP offers MuriGlo, an optical imaging system capable of both two-dimensional 
BLI, fluorescence imaging and three-dimensional bioluminescence tomography (BLT) [63]. Similarly, 
BLT has also been successfully integrated into the iSMAART system and shown accurately targeting 
with quantitative assessment of response in orthotopically implanted, luciferase expressing 4T1 
breast cancer cells [64]. BLI is an attractive imaging modality in radiotherapy studies as it can provide 
target localization information and does not contribute to added dose [65,66], however, research 
efforts are required to develop robust 3D reconstruction algorithms for true tomographical 
representation. 
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In addition to BLI, in vivo fluorescence imaging (FLI) is another optical imaging technique that 
is being applied to radiobiological studies. An interesting approach has been demonstrated 
combining the Cx225 platform with intra-vital, multimodal optical microscopy to study the spatio-
temporal dynamics of tumor microvasculature in radiation response of tumors [67]. Another 
approach combined the iSMAART device with fluorescence molecular tomography (FMT) to localize 
tumors at depth with a localization error of <0.5 mm [19]. 
Finally, a number of imaging methods have been preclinically evaluated but have not been 
explored in the clinic. These include molecular ultrasound using microbubble agents, photoacoustic 
imaging, Raman spectroscopy, as well as a variety of emerging radiotracers, magnetic resonance 
imaging probes and X-ray contrast agents [28,34,46,68–70], which may yet provide important clinical 
advantages in diagnosis and treatment. 
4. Translational Research Opportunities 
Imaging techniques play a central role in patient management to determine tumor-specific 
characteristics and response to therapy. This is particularly evident in radiation oncology where 
imaging is used for diagnosis, treatment planning, response monitoring and to detect adverse effects 
resulting from treatment [35,71,72]. Preclinical investigations integrating anatomical, functional, and 
molecular imaging in the experimental study design allows interrogation of key molecular 
characteristics that can be used to detect and potentially predict radiotherapy response. CT and BLT 
have been successfully integrated with preclinical radiotherapy devices to provide excellent multi-
modal imaging solutions. Using interchangeable beds and immobilization devices, it is also possible 
to develop sequential workflows across different systems allowing co-registration of multiple 
imaging sources with radiotherapy plans that are equally effective and more easily disseminated, 
e.g., sequential PET/MRI systems. Some of the unique research possibilities that these approaches are 
now enabling towards the realization of biologically optimized radiotherapy are explained below. 
4.1. Quantifying Tumor Burden and Response to Therapy 
Evaluation of the tumor burden at diagnosis and during response to therapy is critical in guiding 
treatment decisions, prognosis and radiotherapy planning. Clinically, longitudinal CT scans are used 
to assess volumetric differences in target lesions at baseline and after treatment, which are 
standardized to the Response Evaluation Criteria for Solid Tumors (RECIST) [73,74]. However, 
anatomical observations have limitations in imaging changes post treatment as they fail to accurately 
represent viable tumor cells. 18F-FDG-PET/CT has become established as an important tool in 
radiation oncology to determine primary tumor characteristics, lymph node invasion and metastases. 
This has led to the Positron Emission Tomography (PET) Response Criteria in Solid Tumors 
(PERCIST 1.0) which adopts functional imaging into routine assessment. These criteria also serve as 
a starting point for use in clinical trials when assessing the activity of novel therapies that stabilize 
disease, and has led to revised strategies based on functional rather than anatomical features [75]. 
Currently, no standardized staging or response criteria have been defined for preclinical studies 
where quantification of tumor burden is derived from caliper measurements or longitudinal 
monitoring of regions of interest delineated from imaging. In PET imaging, regions of interest are 
determined from the standardized uptake volume (SUV), defined as the level of tracer accumulation 
normalized to the subject mass. This may also be used to determine progression in cancer models by 
comparing tracer distributions in normal and diseased mice. 
Preclinical efforts are needed towards optimizing PET tracers and evaluating radiotherapy 
response where determining success or failure may guide future treatment decisions such as dose 
boosting or salvage surgery. As tumor response is non-uniform, alterations in the SUVs of tracers 
often occurs prior to tissue changes and so may provide predictive information of response, local 
failure or radioresistance. Preclinical evaluation of 18F-FDG uptake has been determined for different 
doses and irradiated sub-volumes. This important study irradiated high uptake regions with high 
doses and reduced (redistribution approach) or standard doses (dose escalation approach) were 
delivered to the rest of the tumor volume. Minimum tumor growth delay was observed in the mice 
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with dose escalation to the sub-volumes with high FDG uptake [47]. Other preclinical studies 
compare 18F-FMISO, 18F-FAZA and 18F-HX4 to optimize imaging conditions to evaluate tumor 
hypoxia in preclinical models [52–54]. A further study used the hypoxia specific tracer 18F-EF5 to 
determine changes in hypoxia with radiation response. Tracer uptake was correlated with tumor 
growth delay or total control and showed distinct responses corresponding to the uptake of 18F-EF5 
before irradiation, suggesting response can be predicted based on initial 18F-EF5 uptake [49,50]. 
Finally, different imaging techniques can also allow differentiation of tumor and normal tissues 
at a level superior to anatomical imaging. Although technological improvements have reduced the 
risk of normal tissue injury, toxicity causing long-term side effects or interrupted treatment continues 
to occur in subsets of patients and can be critical in defining treatment options. Pre-clinically, CT data 
in free-breathing animals enabled the non-invasive and high-throughput detection of a range of 
pulmonary diseases in mice [76,77]. Moreover, CT was also used to image the radiation-induced lung 
fibrosis longitudinally for up to 9 months post irradiation [78–81]. MRI has also been used to detect 
pulmonary fibrosis in living mice and rats treated with bleomycin [82]. Considering the critical role 
of the immune system in radiotherapy response, imaging approaches capable of visualizing highly 
complex interactions involving multiple cell types are also being developed. 
4.2. Imaging the Immune Response 
The seminal discovery of enhanced antitumor immunity by blockade of the cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) by Allison and colleagues in 1996 [83] has led to the rapid 
development and uptake of immunotherapy as standard of care for many types of cancer [84,85]. 
Currently, over 2000 different immunotherapy compounds are in development, with 26 approved 
immune-oncology (IO) agents already approved for use in the clinic including T-cell targeted 
immuno-modulators, cancer vaccines and cell therapies [85]. The underlying mechanism of action 
for IO agents often leads to abnormal response patterns termed pseudo-progression, and represents 
considerable risk in underestimating response which may lead to early removal of patients from 
treatment. This has resulted in the development of the iRECIST guidelines by the RECIST working 
group for the use of modified criteria in cancer immunotherapy trials [86], which provide information 
concerning tumor size but not biological characteristics of the tumor. 
Given that only 15–30% of patients respond to IO agents as monotherapies, there is a critical 
need for biomarkers to accurately predict response and select patients most likely to respond, and for 
the development of novel combination therapies [87]. Radiotherapy is a promising approach for 
combination with IO due to its multiple immune-modulatory effects, which include natural killer 
(NK) cell activation [88], increased expression of tumor associated antigens [89] and activation of 
immunogenic cell death mediated by damage-associated molecular patterns (DAMPs) [87,90]. 
Limited information is available concerning the molecular imaging changes during response to 
IO agents as monotherapies or in combination with radiotherapy. Molecular imaging has much 
potential to differentiate immune response from tumor progression by targeted labelling of immune 
cells ex vivo, PET reporter gene expression or direct in vivo labelling and provides predictive 
biomarkers of response to IO in combination with radiotherapy [91]. Considering the observed 
dependence of immune effects on dose and fractionation scheme [92,93], major efforts are needed to 
optimize the combination of IO and radiotherapy in preclinical models prior to translation to the 
clinic. Important preclinical studies using syngeneic mouse mammary tumor models with small 
animal radiotherapy have delineated the mechanisms and dose response of radiation induced T cell 
activation through the DNA exonuclease, Trex1. These important findings may guide the selection 
of optimum radiation dose and fractionation in patients treated with immunotherapy [92]. Also, the 
tracer 2’-deoxy-2’-(18F)fluoro-9-β-D-arabinofuranosyl has been identified to have specific cytotoxicity 
in T-lymphocytes compared to other immune cell types and is currently under clinical investigation 
as an indicator of the immune status in cancer patients (NCT03142204). (18F)F-AraG has also been 
used in preclinical studies to image T-cell dynamics, showing up to 1.4-fold higher uptake in a Graft-
versus-Host disease elicited by allogenic hematopoietic cell transplant compared to control mice 
[41,55,56]. 
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4.3. Image-Guided Adaptive Radiotherapy 
Anatomical changes during treatment including tumor growth, regression or weight loss may 
necessitate adaptive planning by modifying the treatment plan based on the most current image to 
prescribe new personalized margins and doses for individual patients [94]. Repeated CT imaging 
during treatment is often used for adaptive re-planning, aiming to integrate sequential imaging in 
the radiotherapy workflow. This has led to the development of MRI-integrated radiotherapy systems 
first conceptualized by Lagendijk and Bakker [95] with two systems now commercially available 
developed by ViewRay and the Philips Elekta Consortium [96,97]. 
In addition to real-time image-guided treatments, spatial variations in tracer uptake offer 
opportunities for dose boosting in sub-volumes of high 18F-FDG uptake or hypoxic regions [98–101]. 
Anatomical and functional imaging are proving essential in defining target volumes, in dose painting 
and adaptive treatments to optimize dose in radio-resistant areas, yet many challenges remain in how 
to best integrate these approaches and determine individualized treatments. Preclinical efforts have 
made towards developing novel technology, with several prototypes for MRI-PET imaging systems 
already developed and incorporated in pilot studies [101]. 
5. Conclusions 
Technological innovations in the delivery of advanced conformal radiotherapy and radiological 
imaging have resulted in improved outcomes for cancer patients receiving radiotherapy. Clinical 
advances have been reverse translated to the laboratory, where research teams are now enabled to 
deliver highly conformal treatments to small volumes under image guidance. These advances 
fundamentally require a better understanding of the radiobiological correspondence between mice 
and humans so that fractionation schedules and dose distributions can be better interpolated in 
experimental models. The synergy of small animal radiotherapy studies with functional imaging has 
high potential to lead to the next generation of innovations in radiation oncology, which may include 
biologically guided treatments using predictive biomarkers to optimize dose, fractionation and 
combination treatments with IO or other molecular targeted agents. 
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